| abstract |
Referring to a compound of formula 1, or a pharmaceutically acceptable salt, this where: X1 is selected from N and CR1; X2 is selected from N and CR2; X3 is selected from N and CR3; and X4 is selected from N and CR4; X13 is NR13 and X14 is CR15R16 or X13 is CH2 and X14 is NR14; L is NR8 and O; r is selected from 0 and 1; s is selected from 0 and 1; R5 is selected from (a) hydrogen, halo, hydroxy, and cyano; and (b) C1-4 alkyl, C3-6 cycloalkyl, and C1-4 alkoxy, each substituted with 0 to 3 optional substituents which are independently selected from halo, oxo and phenyl which is substituted with 0 to 3 optional substituents which are selected. regardless of halo; each R6 and R7 is independently selected halo and C1-3 alkyl, or R6 and R7, together with the carbon atom to which they are attached, form a cycloalkane-C3-4-1,1-diyl; R9 and R10 are each independently selected from a) H, halo, hydroxy, and cyano; (b) C1-4 alkyl, C3-6 cycloalkyl, and C1-4 alkoxy, each substituted with 0 to 3 optional substituents; and (c) phenyl and C1-5 heteroaryl, each substituted with 0 to 3 optional substituents; R11 and R12 are each independently selected from (a) H, halo, hydroxy, and cyano; and (b) C1-4 alkyl, C3-6 cycloalkyl, and C1-4 alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or, among others. A selected compound is 2,2-dimethyl-N- (1-methylpiperidin-4-yl) -3 - ((3-methylpyridin-2-yl) oxy) propanamide. Said compound is derived from piperidinyl-3- (aryloxy) propanamide and propanoates and are modulators of the somatostatin receptor 4 (SSTR4). It also refers to his or her use in treating a disease, disorder, or condition that is selected from Alzheimer's disease, depression, anxiety. |